王莉莉 朱振龍 郝彤

[摘要] 目的 研究Survivin在正常子宮內(nèi)膜、子宮內(nèi)膜不典型增生和子宮內(nèi)膜樣腺癌（EA）三種組織中表達(dá)的差異。 方法 選取華北石油管理局總醫(yī)院2010年1月～2012年6月手術(shù)切除子宮并經(jīng)病理證實(shí)的EA存檔標(biāo)本40例（EA組），經(jīng)診刮或?qū)m腔鏡檢查病理結(jié)果示子宮內(nèi)膜不典型增生20例（AHE組），同時(shí)選取同期因子宮脫垂或子宮肌瘤行子宮切除的正常子宮內(nèi)膜20例作為對(duì)照（CON組）。通過(guò)免疫組織化學(xué)法檢測(cè)三組中Survivin表達(dá)情況的差異。應(yīng)用SPSS 16.0統(tǒng)計(jì)軟件進(jìn)行數(shù)據(jù)分析。 結(jié)果 EA組的Survivin表達(dá)陽(yáng)性率為90%，顯著高于CON組（75%），差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）。在EA組中，組織分級(jí)為G1、G2、G3級(jí)的患者Survivin陽(yáng)性率分別為85.0%、90.9%、100.0%，差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）;手術(shù)-病理分期為Ⅰ期、Ⅱ期、Ⅲ期的患者Survivin陽(yáng)性率分別為62.1%、85.7%、100.0%，差異有統(tǒng)計(jì)學(xué)意義（P < 0.05）;肌層浸潤(rùn)深度<1/2及≥1/2的患者Survivin陽(yáng)性率分別為88.5%、92.9%，差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）;存在淋巴結(jié)轉(zhuǎn)移及無(wú)淋巴結(jié)轉(zhuǎn)移的患者Survivin陽(yáng)性率為100.0%、80.6%，差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）;存在脈管浸潤(rùn)及無(wú)脈管浸潤(rùn)的患者Survivin陽(yáng)性率分別為100.0%、84.2%，差異無(wú)統(tǒng)計(jì)學(xué)意義（P > 0.05）。 結(jié)論 相較于正常子宮內(nèi)膜，EA組織中Survivin表達(dá)顯著增多。Survivin的陽(yáng)性表達(dá)率與EA組織學(xué)分級(jí)和手術(shù)-病理分期相關(guān)，與肌層浸潤(rùn)、淋巴結(jié)轉(zhuǎn)移及有無(wú)脈管浸潤(rùn)無(wú)關(guān)。

[關(guān)鍵詞] 子宮內(nèi)膜樣腺癌;Survivin;免疫組織化學(xué);組織分級(jí);手術(shù)-病理分期

[中圖分類號(hào)] R737.33 ? ? ? ? ?[文獻(xiàn)標(biāo)識(shí)碼] A ? ? ? ? ?[文章編號(hào)] 1673-7210（2015）01（a）-0019-04

Expression of Survivin in endometrial carcinoma

WANG Lili1 ? ZHU Zhenlong2▲ ? HAO Tong3

1.Department of Obstetrics and Gynecology， North-China Petroleum Administration Bureau General Hospital， Hebei Province， Renqiu ? 062552， China; 2.Department of Pathology， the First Hospital， Hebei Medical University， Hebei Province， Shijiazhuang ? 050030， China; 3.Department of Pathology， North-China Petroleum Administration Bureau General Hospital， Hebei Province， Renqiu ? 062552， China

[Abstract] Objective To compare the expression of Survivin in normal endometrium， atypical hyperplasia of endometrium and endometrioid adenocarcinoma. Methods Forty cases of endometrioid adenocarcinoma samples resected from operation and confirmed by pathology were selected as EA group， 20 cases of atypical hyperplasia of endometrium （AHE） confirmed by pathologic from endocervical curettage or hysteroscopy were selected as AHE group， 20 cases of normal endometrium from hysterectomy for uterine prolapse or uterine fibroids were selected as control group （CON group） in North-China Petroleum Administration Bureau General Hospital from January 2010 to June 2012. Expression of Survivin in the three groups were detected by immunohistochemistry method. All the data was analyzed by SPSS 16.0. Results The positive expression rate of Survivin in the EA group was 90%， which was higher than that in the CON group （75%）， with statistically significant difference （P < 0.05）. In EA group， the positive expression rates of Survivin in patients with organization classification of G1， G2， G3 were 85.0%， 90.9% and 100.0%， with statistically significant differences （P < 0.05）; which in panties with surgery-pathological staging of Ⅰ， Ⅱ， Ⅲ were 62.1%， 85.7% and 100.0%， with statistically significant difference （P < 0.05）; which in patients with muscularis invasion depth<1/2 or ≥1/2 were ?88.5% and 92.9%， without statistically significant difference （P > 0.05）; which in patients with lymphatic metastasis or non- metastasis were 100.0% and 80.6%， without statistically significant difference （P > 0.05）; which in patients with vascular invasion or non-vscular invasion were 100.0% and 84.2%， without statistically significant difference （P > 0.05）. Conclusion Compared with normal endometrium， endometrioid adenocarcinoma has higher Survivin expression. The positive expression rates of Survivin are correlated with the histological grade and surgery-pathological stage of EA， but has no relationship with myometrial invasion， lymph node metastasis or vascular invasion.